Barely Significant
← all excerpts

Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference.

Neuropsychiatr Dis Treat · 2010 · PMC2951059 · PMID 20169042

Europe PMCDOI
1
hedged sentence
0.0590
closest p · 1.2× alpha
0.0590
boldest claim

The sentences

showed a trendP = 0.059so close (0.05 < p ≤ 0.1)
Similar data on medication overuse were unavailable from the US trial, but a secondary analysis was performed and showed a trend towards significant group differences ( P = 0.059). 56 In the European trial the responder rate of at least 50% in reduction of migraine days was significant for topiramate (22% vs 0% P = 0.012), but not in the US trial in which only the under 25% reduction in migraine/migrainous days responder rates showed significance. 57 Patients’ disability and quality of life evaluation results were different in both trials.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.